Pretreatment brain states identify likely nonresponse to standard treatments for depression.
BACKGROUND
Treatment approaches for major depressive disorder (MDD) result in approximately one third of patients achieving remission after a first treatment. Added treatment generally improves remission rates, but approximately one third of all patients fail to respond after several treatments (sequential monotherapies or combined treatment). A pretreatment biomarker could help identify these patients. Overactivity of the subcallosal cingulate has been associated with failure of response to treatment in MDD, and it is a potential candidate for such a biomarker.


METHODS
Investigators enrolled 82 patients with MDD currently not receiving treatment in a two-phase treatment study. Patients underwent a fluorodeoxyglucose positron emission tomography scan. After scanning, patients were randomly assigned to 12 weeks of treatment with either escitalopram or cognitive-behavioral therapy (CBT). Patients not achieving remission after 12 weeks of initial treatment were treated with an additional 12 weeks of escitalopram plus CBT. Subcallosal cingulate metabolism was compared between patients who failed to achieve a response and patients who achieved remission as a result of either phase one or phase two treatment. This analysis was followed by a whole-brain analysis making the same comparison.


RESULTS
After two phases of treatment (24 weeks), 36 patients were identified as remitters, 6 patients were responders, and 9 patients were nonresponders. Subcallosal cingulate metabolism was significantly higher in nonresponders than remitters. In the follow-up whole-brain analysis, increased superior temporal sulcus activity was also associated with nonresponse to two treatments.


CONCLUSIONS
Patients with MDD who fail to achieve remission as a result of CBT or escitalopram, either alone or in combination, have a distinct brain metabolic pattern compared with patients who achieve remission as a result of CBT, escitalopram, or their combination.
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia; Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, Georgia.
Callie L
CL
McGrath
Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia.
Mary E
ME
Kelley
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia.
Boadie W
BW
Dunlop
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia; Department of Psychiatry and Department of Surgery, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Paul E
PE
Holtzheimer
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia; Department of Psychology, Emory University, Atlanta, Georgia.
W Edward
WE
Craighead
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia; Department of Neurology, Emory University, Atlanta, Georgia. Electronic address: hmayber@emory.edu.
Helen S
HS
Mayberg
D000328:Adult; D015283:Citalopram / Q000627:therapeutic use*; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000628:therapy*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006179:Gyrus Cinguli / Q000000981:diagnostic imaging / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D016896:Treatment Outcome
D015283:Citalopram; D019788:Fluorodeoxyglucose F18
Antidepressant medication; biomarker; depression; psychotherapy; subcallosal cingulate; superior temporal sulcus